And let's not even begin to discuss 2013, when analysts are forecasting $240 million in Qsymia sales. Again, using current prices, that implies an average of 584,000 patients on drug. Next year, Vivus will face competition from Arena Pharmaceuticals' (ARNA) weight-loss drug Belviq. A third obesity drug from Orexigen Therapeutics (OREX) is still in clinical trials.
Vivus reports third-quarter results on Nov. 6, which will include negligible Qsymia sales since the drug was launched at the end of the quarter. The stock has lost 38% of its value since Qsymia's lauch, reflecting investor uncertainty. Still, don't be surprised to see analysts use Vivus' third-quarter report as a trigger to sharply reduce Qsymia sales forecasts for the rest of this year and next.
At least that's what the analysts should do, if they were looking at the Qsymia prescription data objectively.
-- Reported by Adam Feuerstein in Boston.Follow @AdamFeuerstein
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV